XML 45 R33.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Warrants | 3 Months Ended
--- | ---
Mar. 31, 2024
Warrants [Abstract] |
Warrants |
| 27. | Warrants
On December 8, 2020, the Company entered in a securities purchase agreement with certain institutional investors, pursuant to which the Company issued in a registered direct offering, an aggregate of 9,489,800 shares of its common stock at a price of $5.18 per share, for aggregate gross proceeds to the Company of approximately $49 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. As part of the transaction, the institutional investors also received warrants (“Investor Warrants”) for the purchase of up to 3,795,920 shares of the Company’s common stock at an exercise price of $6.46 per share exercisable for 36 months from the date of issuance. In addition, the placement agent for this transaction also received warrants (“Placement Agent Warrants”) for the purchase of up to 379,592 shares of the Company’s common stock at an exercise price of $6.475 per share exercisable for 36 months after 6 months from the issuance. The Company has performed a thorough reassessment of the terms of its warrants with reference to the provisions of ASC Topic 815-40-15-7I, regarding its exposure to changes in currency exchange rates. This reassessment has led to the management’s conclusion that the Company’s warrants issued to the investors should not be considered indexed to the Company’s own stock because the warrants are denominated in U.S. dollar, which is different from the Company’s functional currency, Renminbi. Warrants are remeasured at fair value with changes in fair value recorded in earnings in each reporting period. On February 8, 2021, the Company entered into another securities purchase agreement with the same investors, pursuant to which the Company issued in a registered direct offering, an aggregate of 8,939,976 shares of common stock of the Company at a per share purchase price of $7.83. In addition, the Company issued to the investors (i) in a concurrent private placement, the Series A-1 warrants to purchase a total of 4,469,988 shares of common stock, at a per share exercise price of $7.67 and exercisable for 42 months from the date of issuance; (ii) in the registered direct offering, the Series B warrants to purchase a total of 4,469,988 shares of common stock, at a per share exercise price of $7.83 and exercisable for 90 days from the date of issuance; and (iii) in the registered direct offering, the Series A-2 warrants to purchase up to 2,234,992 shares of common stock, at a per share exercise price of $7.67 and exercisable for 45 months from the date of issuance. The Company received gross proceeds of approximately $70 million from the registered direct offering and the concurrent private placement, before deducting fees to the placement agent and other estimated offering expenses of $5.0 million payable by the Company. In addition, the placement agent for this transaction also received warrants (“Placement Agent Warrants”) for the purchase of up to 446,999 shares of the Company’s common stock at an exercise price of $9.204 per share exercisable for 36 months after 6 months from the issuance. On May 10, 2021, the Company entered into that Amendment No. 1 to the Series B Warrant (the “Series B Warrant Amendment”) with each of the holders of the Company’s outstanding Series B warrants. Pursuant to the Series B Warrant Amendment, the term of the Series B warrants was extended from May 11, 2021 to August 31, 2021. As of the date of this report, Series B warrant, along with Series A-2 warrants, had both expired. There was a total of 5,296,579 warrants issued and outstanding as of March 31, 2024. The fair value of the outstanding warrants was calculated using Binomial Model based on backward induction with the following assumptions: Warrants issued in the 2020 Financing
Appraisal Date |  | December 31, 2023 |  |  | December 31, 2023 |
Market price per share (USD/share) |  | $ | n/a |  |  | $ | 1.05 |
Exercise price (USD/price) |  |  | n/a |  |  |  | 6.475 |
Risk free rate |  |  | n/a |  |  |  | 5.3 | %
Dividend yield |  |  | n/a |  |  |  | 0.0 | %
Expected term/ Contractual life (years) |  |  | n/a |  |  |  | 0.4 years |
Expected volatility |  |  | n/a |  |  |  | 53.9 | %
Appraisal Date |  | March 31, 2024 |  |  | March 31, 2024 |
Market price per share (USD/share) |  | $ | n/a |  |  | $ | 1.04 |
Exercise price (USD/price) |  |  | n/a |  |  |  | 6.475 |
Risk free rate |  |  | n/a |  |  |  | 5.4 | %
Dividend yield |  |  | n/a |  |  |  | 0.0 |
Expected term/ Contractual life (years) |  |  | n/a |  |  |  | 0.2 years |
Expected volatility |  |  | n/a |  |  |  | 54.8 | %
Warrants issued in the 2021 Financing Warrants holder
|  | Investor Warrants Series A1 |  |  | Placement Agent Warrants |
Appraisal Date |  | December 31, 2023 |  |  | December 31, 2023 |
Market price per share (USD/share) |  |  | 1.05 |  |  |  | 1.05 |
Exercise price (USD/price) |  |  | 7.67 |  |  |  | 9.204 |
Risk free rate |  |  | 5.1 | % |  |  | 5.1 | %
Dividend yield |  |  | 0.0 | % |  |  | 0.0 | %
Expected term/ Contractual life (years) |  |  | 0.6 year |  |  |  | 0.6 year |
Expected volatility |  |  | 63.0 | % |  |  | 60.3 | %
Warrants holder
|  | Investor Warrants Series A1 |  |  | Placement Agent Warrants |
Appraisal Date |  | March 31, 2024 |  |  | March 31, 2024 |
Market price per share (USD/share) |  |  | 1.04 |  |  |  | 1.04 |
Exercise price (USD/price) |  |  | 7.67 |  |  |  | 9.204 |
Risk free rate |  |  | 5.3 | % |  |  | 5.3 | %
Dividend yield |  |  | 0.0 | % |  |  | 0.0 | %
Expected term/ Contractual life (years) |  |  | 0.4 years |  |  |  | 0.4 years |
Expected volatility |  |  | 58.4 | % |  |  | 58.4 | %
The following is a reconciliation of the beginning and ending balances of warrants liability measured at fair value on a recurring basis using Level 3 inputs:
|  | December 31, 2023 |  |  | March 31, 2024 |
Balance at the beginning of the year/ period |  | $ | 136,000 |  |  | $ | - |
Warrants issued to institution investors |  |  | - |  |  |  | - |
Warrants issued to placement agent |  |  | - |  |  |  | - |
Warrants redeemed |  |  | - |  |  |  | - |
Fair value change of the issued warrants included in earnings |  |  | (136,000 | ) |  |  | - |
Balance at end of year/ period |  |  | - |  |  |  | - |
The following is a summary of the warrant activity:
|  | Number of Warrants |  |  | Average Exercise Price |  |  | Weighted Average Remaining Contractual Term in Years |
Outstanding at January 1, 2024 |  |  | 5,296,579 |  |  | $ | 7.71 |  |  |  | 0.60 |
Exercisable at January 1, 2024 |  |  | 5,296,579 |  |  | $ | 7.71 |  |  |  | 0.60 |
Granted |  |  | - |  |  |  | - |  |  |  | - |
Exercised / surrendered |  |  | - |  |  |  | - |  |  |  | - |
Expired |  |  | - |  |  |  | - |  |  |  | - |
Outstanding at March 31, 2024 |  |  | 5,296,579 |  |  | $ | 7.71 |  |  |  | 0.35 |
Exercisable at March 31, 2024 |  |  | 5,296,579 |  |  | $ | 7.71 |  |  |  | 0.35 |

X
- Definition Warrants disclosure. + References No definition available. + Details
Name: | cbat_WarrantsTextBlock
Namespace Prefix: | cbat_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_WarrantsAndRightsNoteDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration